Oral News and Research

RSS

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

Health officials to attend International Summit on Tuberculosis and Diabetes in Bali, Indonesia

Health officials from the governments of Indonesia and India will join advocates, civil society groups, researchers and businesses from Asia, Europe, Latin America and North America in Bali, Indonesia on 2-3 November at the world’s first International Summit on Tuberculosis (TB) and Diabetes in an effort to avert a global health crisis.

7 Oct 2015

New capsule form of FMT raises hopes for treating C. difficile infection

A new capsule form of faecal microbiota transplantation (FMT) has raised hopes that this effective treatment for Clostridium difficile (C. difficile) infection and other bowel conditions might soon become mainstream. A recently-reported study confirmed that capsules containing a frozen suspension of faecal material harvested from healthy unrelated donors was well tolerated and effectively resolved diarrhoea in 90% of patients with difficult-to-treat C. difficile infection.

7 Oct 2015

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Researchers from Brigham and Women's Hospital and the University of Murcia, Spain, have shed new light on why people who carry a common genetic mutation may be more at risk for developing type 2 diabetes. By carefully studying healthy subjects, researchers were able to chart the effect of melatonin supplements on blood sugar control.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.

6 Oct 2015

Vaccination against type 1 diabetes may soon be available to young children

A vaccination against type 1 diabetes will soon also be available to young children: the Pre-POINTearly vaccination study will involve children between the ages of six months and two years from across Germany who have a first-degree relative with type 1 diabetes.

6 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Postmenopausal women who are not aware of VVA consequences continue to experience pain during sex

Results from qualitative research of postmenopausal women with vulvar and vaginal atrophy (VVA) show that they recognize the significant physical, emotional and psychological consequences of untreated dyspareunia (painful sex) yet they continue to suffer because of misperceptions about the condition and a general lack of understanding about treatment options.

1 Oct 2015

Research shows more than 30,000 women die from cardiovascular disease in UK

More than 30,000 women die from coronary heart disease in the UK every year with over 700,000 women living with the consequences of heart disease and stroke, according to research published by The British Heart Foundation ahead of World Heart Day on 29th September.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

While emphasis is often placed on keeping athletes and outdoor enthusiasts properly hydrated, too much water can be just as dangerous. Exercise-associated hyponatremia (EAH), also known as water intoxication, results in an extreme, and potentially fatal, sodium imbalance.

30 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Philips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015

Philips Respironics, a business of Royal Philips, will showcase its latest portfolio of sleep-disordered breathing and respiratory solutions September 26-29 at the European Respiratory Society (ERS) International Congress 2015 in Amsterdam. At booth 1.H_01, Hall 1, clinicians can experience the latest Philips sleep-disordered breathing solutions and new options for COPD management that connect and support the patient, clinician and caregiver to improve patient care and help patients to live active lives.

From Philips Healthcare 28 Sep 2015

Interaction between rhinovirus and nasal microbiota in early life persists over time

The interaction between infections and the microbiota during infancy in the lungs could help provide clues to disease development later in life, according to the findings of a new study.

28 Sep 2015

Oral News and Research

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Health officials to attend International Summit on Tuberculosis and Diabetes in Bali, Indonesia

New capsule form of FMT raises hopes for treating C. difficile infection

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

First patients screened in Axovant's phase 3 study of RVT-101

Vaccination against type 1 diabetes may soon be available to young children

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Tris Pharma announces launch of generic TUSSIONEX

Postmenopausal women who are not aware of VVA consequences continue to experience pain during sex

Research shows more than 30,000 women die from cardiovascular disease in UK

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

New drug works better than current treatments for advanced kidney cancer

Philips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015

Interaction between rhinovirus and nasal microbiota in early life persists over time

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News